ReviewFrontiers in pharmacology2019
Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity Against Cancer and Viral Infection.
Review in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- One-year consolidation with Ponatinib 15 mg in chronic myeloid leukaemia on deep molecular response with Imatinib.Annals of hematology · 2026Trial
- Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma.Journal for immunotherapy of cancer · 2021Trial
- Chronic Myeloid Leukemia After Liver Transplantation and the Role of Immunosuppression: A Case Report.Cureus · 2026Article
- Enhancing CAR T cells function: role of immunomodulators in cancer immunotherapy.Clinical and experimental medicine · 2024Review
- Article
- Sustained antiviral response againstFrontiers in pharmacology · 2024Article
- Improving the treatment of bacterial infections caused by multidrug-resistant bacteria through drug repositioning.Frontiers in pharmacology · 2024Review
- Article
- Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs.Journal of translational medicine · 2023Article
- Dasatinib-induced spleen contraction leads to transient lymphocytosis.Blood advances · 2023Article
- Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging.Pharmaceutics · 2023Review
- Management of chronic myelogenous leukemia with COVID-19 and hepatitis B.Frontiers in oncology · 2023Review
- Successful Treatment with Brigatinib after Alectinib-Induced Hemolytic Anemia in Patients with Metastatic Lung Adenocarcinoma-A Case Series.Current oncology (Toronto, Ont.) · 2022Article
- Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity.Immunologic research · 2022Review
- COVID-19 Impact on Chronic Myeloid Leukemia Patients.Journal of personalized medicine · 2022Article
- Targeting Host Tyrosine Kinase Receptor EPHA2 Signaling Affects Uropathogen Infection in Human Bladder Epithelial Cells.Pathogens (Basel, Switzerland) · 2022Article
- Unleashing the power of NK cells in anticancer immunotherapy.Journal of molecular medicine (Berlin, Germany) · 2022Review
- Pharmacologic control of homeostatic and antigen-driven proliferation to target HIV-1 persistence.Biochemical pharmacology · 2021Article
- Chronic Myeloid Leukemia in Children: Immune Function and Vaccinations.Journal of clinical medicine · 2021Review
- Treatment-Free Remission-A New Aim in the Treatment of Chronic Myeloid Leukemia.Journal of personalized medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tyrosine kinase inhibitors (TKIs) of aberrant tyrosine kinase (TK) activity have been widely used to treat chronic myeloid leukemia (CML) for decades in clinic. An area of growing interest is the reported ability of TKIs to induce immunomodulatory effects with anti-tumor and anti-viral activity, which appears to be mediated by directly or indirectly acting on immune cells. In selected cases of patients with CML, TKI treatment may be interrupted and a non-drug remission may be observed. In these patients, an immune mechanism of increased anti-tumor cytotoxic activity induced by chronic administration of TKIs has been suggested. TKIs increase some populations of natural killer (NK), NK-LGL, and T-LGLs cells especially in dasatinib treated CML patients infected with cytomegalovirus (CMV). In addition, dasatinib increases responses against CMV and is able to inhibit HIV replication
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.